1%, respectively, in 12 patients with
Grade 1 nausea and emesis, which occurred in 5 patients was the only valacyclovir-related
Acyclovir is a guanosine analog used to treat herpes simplex, varicella zoster, herpes zoster
Since the drug absorption site is the upper segment of the small intestine so we hypothesised that absorption of acyclovir
The bioavailability of acyclovir in humans is between 10% and 20%, and the The low bioavailability of acyclovir is attributed to
3 fold higher (p < 0
Although acyclovir is prescribed in the management of herpes simplex encephalitis (HSE), the disease has a poor prognosis, particularly if the treatment is delayed, reaching mortality rates of 70% if left
Acyclovir is an antiviral drug poorly absorbed in the gastrointestinal tract due to its hydrophilicity, with low oral bioavailability (~20%)
The oral bioavailability of penciclovir is poor (<5%)
02-9
, valacyclovir (VACV Unlike nucleoside analogs, such as acyclovir, the antiviral activity of amenamevir is not affected by the viral replication cycle and is exhibited by inhibiting viral helicase-primase activity after binding to the helicase-primase complex [8,19]
Various strategies have been investigated to improve the cellular permeability of acyclovir
Because acyclovir is a narrow absorption window drug, it has a poor bioavailability of 10-20 % and a short half-life (t 1/2) of 2
The poor absorption is considered to be a result of characteristics of the drug itself and not its delivery vehicle (De Miranda and Blum, 1983)
Introduction
in cytomegalovirus (CMV)- seronegative transplant recipients] and suppression of latent disease (e
Since then, work has been ongoing to improve the weaknesses that have now been identified: a narrow time window for therapeutic success, resistance in immunocompromised patients
The synthesis of valacyclovir, the L-valine ester of ACV (bioavailability of about 54%) overcame the problem of poor oral ACV bioavailability